Abstract:To observe and discuss the clinical effect of adjuvant drug therapy after arthroscopic debridement in patients with knee osteoarthritis. Methods 114 cases of knee osteoarthritis were selected from January 2015 to June 2016. The patients were numbered in order of admission. The odd-numbered patients were enrolled in the observation group (n = 57) and the even-numbered patients were enrolled in the control group (n = 57). The patients in the control group were only treated with arthroscopic debridement, while the patients in the observation group were injected sodium hyaluronate and ropivacaine as an adjuvant therapy. Then observe the clinical efficacy of the two groups. Results The clinical excellent rate of the observation group was higher than that in the control group (P < 0.05); the visual analogue score (VAS) of the observation group was significantly lower than that of the control group (P < 0.05) on the 1st, 7th, 14th, 28th and 56th day after the treatment; and the HSS score of the observation group was obvious at the 1st, 4th, 12th, 24th and 48th week after the treatment. It was significantly higher than that in the control group (P < 0.05). Conclusion As an adjuvant therapy of arthroscopic debridement in treatment of knee osteoarthritis, the injection of sodium hyaluronate and ropivacaine can further improve the clinical efficacy, clinical symptoms and knee function of patients, and the safety of the treatment is high, so it is worthy of clinical application.